Hims & Hers Shares Rise 9% Amid Peptide Pipeline and Novo Nordisk Partnership
Hims & Hers (HIMS) shares rose 9% as investors anticipate growth from its peptide pipeline and a partnership with Novo Nordisk (NVO) to distribute Wegovy. The stock has surged 49% in five trading sessions, driven by renewed FDA interest in peptides and a new distribution deal, despite a 70% expected decline in Q1 EPS.
Topics: FDA GLP-1 market partnerships pharmaceuticals stock price movement